Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) EBIT Margin: 2018-2023

Historic EBIT Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -8,981.45%.

  • Denali Therapeutics' EBIT Margin fell 596133.00% to -8,981.45% in Q3 2023 from the same period last year, while for Sep 2023 it was -49.73%, marking a year-over-year increase of 23260.00%. This contributed to the annual value of -59.51% for FY2023, which is 25465.00% up from last year.
  • According to the latest figures from Q3 2023, Denali Therapeutics' EBIT Margin is -8,981.45%, which was down 15,595.10% from 57.96% recorded in Q2 2023.
  • Denali Therapeutics' EBIT Margin's 5-year high stood at 77.04% during Q4 2020, with a 5-year trough of -8,981.45% in Q3 2023.
  • Over the past 3 years, Denali Therapeutics' median EBIT Margin value was -616.28% (recorded in 2021), while the average stood at -1,557.59%.
  • Per our database at Business Quant, Denali Therapeutics' EBIT Margin surged by 300,596bps in 2019 and then crashed by 596,133bps in 2023.
  • Quarterly analysis of 5 years shows Denali Therapeutics' EBIT Margin stood at -1,236.26% in 2019, then soared by 131,330bps to 77.04% in 2020, then crashed by 69,332bps to -616.28% in 2021, then plummeted by 40,817bps to -1,024.45% in 2022, then tumbled by 596,133bps to -8,981.45% in 2023.
  • Its EBIT Margin was -8,981.45% in Q3 2023, compared to 57.96% in Q2 2023 and -343.80% in Q1 2023.